Arca
Skip to content
Tools
Tools

Hemophilia B

Drug research and approvals for hemophilia B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 31 studies of hemophilia B are recruiting on ClinicalTrials.gov, Health Canada has authorized 26 drug trials for it since 2013, FDA has 17 approved and 12 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 31
  • Trials authorized in Canada: 26
  • FDA orphan approvals: 17
  • EU medicines: 7

Recruiting now

Newest posted first, of 31 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 10

Phase 3 4

Phase 2 3

Phase 1 or earlier 2

How its trials ended

258 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 66 whose ending is known, 62% met their primary endpoint, 0% missed it and 38% stopped early.

  • Completed, result not reported11745%
  • Ongoing5923%
  • Met its primary endpoint4116%
  • Status unknown166%
  • Stopped: other or unclear125%
  • Stopped: sponsor or business decision104%
  • Stopped: enrollment or feasibility31%

Trials authorized in Canada

The 10 newest of 26; search them all in Canada trials
Aug 20, 2025An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…Fitusiran (SAR439774)Sanofi-Aventis Canada IncOngoing
May 9, 2025A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR604 in healthy…SR604Equilibra Bioscience LLCClosed
Aug 22, 2024A phase 1/2 dose escalation and expansion study of BE-101 for the treatment of adults with moderately severe or severe hemophilia BBE-101Be BiopharmaPending
Jun 21, 2024A two-part open-label study of REGV131-LNP1265, a crispr/CAS9-based coagulation factor ix gene insertion therapy in participants with hemophilia BREGV131-LNP1265RegeneronOngoing
Aug 16, 2023Phase 3b, open-label, multicenter, single-dose study investigating efficacy and safety of CSL222 (etranacogene dezaparvovec) gene therapy administered to adult…CSL222 (etranacogene dezaparvovec)CSLOngoing
Mar 15, 2023A global, open-label study to investimite the efficacy and safety of serpinpc in subjects with hemophilia B with inhibitorsSerpinpcApcintex LimitedPending
Mar 9, 2023A global, open-label, adaptive design study to investigate the efficacy and safety of serpinpc in subjects with severe hemophilia A or moderately severe to…SerpinpcApcintex LimitedOngoing
Oct 31, 2022A phase 3, single-arm, multicenter, multinational, open-label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male…Fitusiran (SAR439774)Sanofi-Aventis Canada IncOngoing
Aug 30, 2022An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of marstacimab prophylaxis in severe (coagulation factor activity…Marstacimab (PF-06741086)PfizerOngoing
Dec 21, 2021Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or b with or…ConcizumabNovo NordiskOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 29
Jun 5, 2026HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with…Pfizer Inc.Approved
Jul 31, 2025AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Mar 28, 2025QfitliaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with…Genzyme CorporationApproved
Dec 20, 2024AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Oct 11, 2024HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Pfizer Inc.Approved
Apr 25, 2024BeqvezTreatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis…Pfizer Inc.Approved
Nov 22, 2022HemgenixTreatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current…CSL Behring LLCApproved
Jul 29, 2022RebinynRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency)Novo Nordisk, Inc.Approved
Oct 5, 2021BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency…Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Approved
Jun 26, 2020BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor…Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Approved
Mar 4, 2016IdelvionIndicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of…CSL Behring, LLCApproved
Sep 12, 2014RixubisAdults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine…Takeda Pharmaceuticals U.S.A., Inc.Approved
Mar 28, 2014AlprolixAdults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to…Bioverativ Therapeutics, Inc.Approved
Jun 26, 2013RixubisAdults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to…Takeda Pharmaceuticals U.S.A., Inc.Approved
Feb 11, 1997BeneFixFor the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas…Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.Approved

Medicines authorised in the EU

Newest first
Feb 20, 2023HemgenixEtranacogene dezaparvovec · orphanCSL Behring GmbHEMA ↗
Jun 2, 2017RefixiaNonacog beta pegolNovo Nordisk A/SEMA ↗
May 12, 2016AlprolixEftrenonacog alfa · orphanSwedish Orphan Biovitrum AB (publ)EMA ↗
May 11, 2016IdelvionAlbutrepenonacog alfa · orphanCSL Behring GmbHEMA ↗
Dec 19, 2014RixubisNonacog gammaBaxalta Innovations GmbHEMA ↗
Aug 27, 1997BeneFIXNonacog alfaPfizer Europe MA EEIGEMA ↗
Feb 23, 1996NovoSevenEptacog alfa (activated)Novo Nordisk A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.